MENU
THNR
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
THNR
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for THNR with price predictions
Oct 22, 2026

Momentum Indicator for THNR turns positive, indicating new upward trend

THNR saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator turned positive. In 32 of the 37 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where THNR's RSI Indicator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for THNR just turned positive on October 19, 2026. Looking at past instances where THNR's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.

Following a +2.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in 111 of 132 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

THNR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for THNR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Regeneron Pharmaceuticals (NASDAQ:REGN), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF (THNR) ETF is 168.49B. The market cap for tickers in the group ranges from 1.56B to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is GPCR at 1.56B.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF (THNR) ETF was 3%. For the same ETF, the average monthly price growth was -3%, and the average quarterly price growth was 2%. KLRA experienced the highest price growth at 13%, while VKTX experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF (THNR) ETF was -31%. For the same stocks of the ETF, the average monthly volume growth was -28% and the average quarterly volume growth was -46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 41
Price Growth Rating: 42
SMR Rating: 68
Profit Risk Rating: 66
Seasonality Score: 22 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
Amplify ETF Trust3250 Lacey Road, Suite 130Downers Grove
Phone
(630) 464-7600
Web
N/A
Momentum Indicator for THNR turns positive, indicating new upward trend